MET and cancer: In order to assess the efficacy of compound 1D228 as an anti-tumor agent, we conducted immune blotting to examine the expression levels of c-Met in various cancer cell lines, including A549, MCF7, HeLa, MDAMB-231, HEPG2, MHCC97H, and MKN45.